US4650750A
(en)
|
1982-02-01 |
1987-03-17 |
Giese Roger W |
Method of chemical analysis employing molecular release tag compounds
|
US4709016A
(en)
|
1982-02-01 |
1987-11-24 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
US5516931A
(en)
|
1982-02-01 |
1996-05-14 |
Northeastern University |
Release tag compounds producing ketone signal groups
|
US5650270A
(en)
|
1982-02-01 |
1997-07-22 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
US5217866A
(en)
|
1985-03-15 |
1993-06-08 |
Anti-Gene Development Group |
Polynucleotide assay reagent and method
|
US5360811A
(en)
|
1990-03-13 |
1994-11-01 |
Hoechst-Roussel Pharmaceuticals Incorporated |
1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents
|
JP3545461B2
(ja)
|
1993-09-10 |
2004-07-21 |
エーザイ株式会社 |
二環式ヘテロ環含有スルホンアミド誘導体
|
AU4596096A
(en)
|
1994-09-06 |
1996-03-27 |
Banyu Pharmaceutical Co., Ltd. |
Novel carbapenem derivative
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
US6306663B1
(en)
|
1999-02-12 |
2001-10-23 |
Proteinex, Inc. |
Controlling protein levels in eucaryotic organisms
|
JP4078074B2
(ja)
|
1999-12-10 |
2008-04-23 |
ファイザー・プロダクツ・インク |
ピロロ[2,3−d]ピリミジン化合物
|
DE10002509A1
(de)
|
2000-01-21 |
2001-07-26 |
Gruenenthal Gmbh |
Substituierte Glutarimide
|
JP2003525296A
(ja)
|
2000-02-28 |
2003-08-26 |
スージェン・インコーポレーテッド |
キナーゼ阻害剤としての3−(ピロリルラクトン)−2−インドリノン化合物
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
US7208157B2
(en)
|
2000-09-08 |
2007-04-24 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
WO2002020740A2
(fr)
|
2000-09-08 |
2002-03-14 |
California Institute Of Technology |
Medicament chimere de ciblage de proteolyse
|
AU2002307217A1
(en)
*
|
2001-03-28 |
2002-10-15 |
University Of South Florida |
Materials and methods for treatment of cancer and identification of anti-cancer compounds
|
JP3836436B2
(ja)
|
2001-04-27 |
2006-10-25 |
全薬工業株式会社 |
複素環式化合物及びそれを有効成分とする抗腫瘍剤
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
DE60325740D1
(de)
|
2002-08-14 |
2009-02-26 |
Silence Therapeutics Ag |
Verwendung von protein-kinase-n-beta
|
WO2004089925A1
(fr)
|
2003-04-03 |
2004-10-21 |
Semafore Pharmaceuticals, Inc. |
Promedicaments d'inhibiteurs de pi-3 kinase
|
DK1644363T3
(da)
|
2003-05-30 |
2012-05-29 |
Gemin X Pharmaceuticals Canada Inc |
Triheterocykliske forbindelser, sammensætninger og fremgangsmåder til behandling af cancer eller virussygdomme
|
EP1692153A4
(fr)
|
2003-07-03 |
2007-03-21 |
Univ Pennsylvania |
Inhibition de l'expression d'une syk kinase
|
WO2005058829A1
(fr)
|
2003-12-11 |
2005-06-30 |
Board Of Regents, The University Of Texas System |
Composes pour traiter des maladies associees a une proliferation cellulaire
|
JP4398263B2
(ja)
|
2004-01-13 |
2010-01-13 |
富士通株式会社 |
経路設計方法
|
US7436318B2
(en)
|
2004-04-19 |
2008-10-14 |
Atg Designworks, Llc |
Self contained device for displaying electronic information
|
LT2612862T
(lt)
|
2004-05-13 |
2017-01-25 |
Icos Corporation |
Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
|
US20060005147A1
(en)
|
2004-06-30 |
2006-01-05 |
Hammack Jason L |
Methods and systems for controlling the display of maps aboard an aircraft
|
US20070010428A1
(en)
|
2004-09-03 |
2007-01-11 |
Mcmurray John S |
Inhibitors of signal transduction and activator of transcription 3
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
DK1856135T3
(da)
|
2005-01-19 |
2010-04-12 |
Rigel Pharmaceuticals Inc |
Prodrugs af 2,4-pyrimidindiamin-forbindelser og deres anvendelser
|
US20060247318A1
(en)
|
2005-02-25 |
2006-11-02 |
Hui Song |
Small molecule inhibitors of STAT3 and the uses thereof
|
US7812135B2
(en)
|
2005-03-25 |
2010-10-12 |
Tolerrx, Inc. |
GITR-binding antibodies
|
WO2007040650A2
(fr)
|
2005-05-12 |
2007-04-12 |
Abbott Laboratories |
Promoteurs d'apoptose
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
SI1907424T1
(sl)
|
2005-07-01 |
2015-12-31 |
E. R. Squibb & Sons, L.L.C. |
Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
|
US7402325B2
(en)
|
2005-07-28 |
2008-07-22 |
Phoenix Biotechnology, Inc. |
Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
|
US20080139456A1
(en)
|
2005-09-30 |
2008-06-12 |
Burke Terrence R |
Macrocyclic Sh2 Domain Binding Inhibitors
|
EA024305B1
(ru)
|
2005-10-07 |
2016-09-30 |
Экселиксис, Инк. |
Ингибиторы фосфатидилинозит-3-киназы и их применение
|
BRPI0617364A2
(pt)
|
2005-10-13 |
2011-07-26 |
Orchid Res Lab Ltd |
compostos heterocÍclicos como inibidores de pstat3/il-6
|
BR122021011788B1
(pt)
|
2005-11-01 |
2022-01-25 |
Impact Biomedicines, Inc |
Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
|
MY159449A
(en)
|
2005-12-13 |
2017-01-13 |
Incyte Holdings Corp |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
|
WO2007078990A2
(fr)
|
2005-12-23 |
2007-07-12 |
Zealand Pharma A/S |
Composés modifiés mimétiques de la lysine
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
NZ572812A
(en)
|
2006-04-26 |
2010-09-30 |
Hoffmann La Roche |
THIENO [3, 2-D] PYRIMIDINE Indazole DERIVATIVE USEFUL AS PI3K INHIBITOR
|
WO2007136858A2
(fr)
|
2006-05-19 |
2007-11-29 |
H. Lee Moffitt Cancer Center & Research Institute |
Petites molécules inhibitrices de stat3 ayant une activité antitumorale
|
EP2532235A1
(fr)
|
2006-09-22 |
2012-12-12 |
Pharmacyclics, Inc. |
Inhibiteurs de la tyrosine kinase de bruton
|
UA95978C2
(ru)
|
2006-10-02 |
2011-09-26 |
Оцука Фармас'Ютікел Ко., Лтд. |
Ингибитор активации stat3/5
|
WO2008067270A1
(fr)
|
2006-11-27 |
2008-06-05 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Inhibiteurs de liaison au domaine grb2 sh2 macrocyclique
|
KR101566840B1
(ko)
|
2007-03-12 |
2015-11-06 |
와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 |
페닐 아미노 피리미딘 화합물 및 이의 용도
|
US8394794B2
(en)
|
2007-03-23 |
2013-03-12 |
Regents Of The University Of Minnesota |
Therapeutic compounds
|
EP1987839A1
(fr)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Anticorps monoclonal cytotoxique anti-LAG-3 et son utilisation pour le traitement ou la prévention d'un rejet de greffe d'organe et de maladies auto-immunes
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
WO2008156644A2
(fr)
|
2007-06-14 |
2008-12-24 |
Frank David A |
Modulateurs de stat
|
EP3124046B1
(fr)
|
2007-07-12 |
2019-12-25 |
GITR, Inc. |
Thérapies combinées utilisant des molécules de liaison gitr
|
WO2009032338A1
(fr)
|
2007-09-09 |
2009-03-12 |
University Of Florida Research Foundation |
Agents thérapeutiques à base d'apratoxine : mécanisme et procédés de traitement
|
EP2044949A1
(fr)
|
2007-10-05 |
2009-04-08 |
Immutep |
Utilisation de lag-3 recombinant ou ses dérivatifs pour déclencher la réponse immune des monocytes
|
CA2932121A1
(fr)
|
2007-11-30 |
2009-06-11 |
Newlink Genetics Corporation |
Inhibiteurs de l'ido
|
FR2927330B1
(fr)
|
2008-02-07 |
2010-02-19 |
Sanofi Aventis |
Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
|
UA101493C2
(ru)
|
2008-03-11 |
2013-04-10 |
Инсайт Корпорейшн |
Производные азетидина и циклобутана как ингибиторы jak
|
CN102083429B
(zh)
|
2008-04-24 |
2014-05-28 |
新联基因公司 |
Ido抑制剂
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
KR20110033922A
(ko)
|
2008-07-08 |
2011-04-01 |
더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 |
전사의 신호 변환자 및 활성제(stats)의 증식 및 활성화의 신규한 억제제
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
EP2373658A4
(fr)
|
2008-12-08 |
2012-05-23 |
Univ Michigan Office Of Technology Transfer |
Inhibiteurs de stat3 et méthodes thérapeutiques les utilisant
|
CN114835812A
(zh)
|
2008-12-09 |
2022-08-02 |
霍夫曼-拉罗奇有限公司 |
抗-pd-l1抗体及它们用于增强t细胞功能的用途
|
US8921037B2
(en)
|
2008-12-16 |
2014-12-30 |
Bo Han |
PF4-depleted platelet rich plasma preparations and methods for hard and soft tissue repair
|
US8841257B2
(en)
|
2009-04-10 |
2014-09-23 |
Board Of Regents, The University Of Texas System |
Inhibitors of STAT3 and uses thereof
|
JP2012524106A
(ja)
|
2009-04-15 |
2012-10-11 |
ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション |
二重jak2/stat3阻害剤としてのクルクミン類似体ならびにその同じ物を作る、および用いる方法
|
RU2595409C2
(ru)
|
2009-09-03 |
2016-08-27 |
Мерк Шарп И Доум Корп., |
Анти-gitr-антитела
|
EP2493862B1
(fr)
|
2009-10-28 |
2016-10-05 |
Newlink Genetics Corporation |
Dérivés imidazole comme inhibiteurs de l'ido
|
CA2781706A1
(fr)
|
2009-11-24 |
2011-06-03 |
The Ohio State University |
Inhibiteurs de facteur de transcription et compositions, formulations et procedes apparentes
|
ES2557454T3
(es)
|
2009-12-10 |
2016-01-26 |
F. Hoffmann-La Roche Ag |
Anticuerpos que se unen al dominio extracelular 4 de CSF1R humana y su utilización
|
US8445517B2
(en)
|
2009-12-11 |
2013-05-21 |
Dana-Farber Cancer Institute |
Stat modulators
|
CN102725287B
(zh)
|
2009-12-28 |
2015-07-01 |
一般社团法人创药分子谷项目支援机构 |
1,3,4-噁二唑-2-甲酰胺化合物
|
CN106279416B
(zh)
|
2010-03-04 |
2019-08-30 |
宏观基因有限公司 |
与b7-h3反应性的抗体、其免疫学活性片段及其用途
|
EP2542587A1
(fr)
|
2010-03-05 |
2013-01-09 |
F. Hoffmann-La Roche AG |
Anticorps dirigés contre le csf-1r humain et utilisations associées
|
MX336682B
(es)
|
2010-03-05 |
2016-01-27 |
Hoffmann La Roche |
Anticuerpos contra csf-1r humanos y usos de los mismos.
|
CN106977603B
(zh)
|
2010-05-04 |
2020-11-27 |
戊瑞治疗有限公司 |
结合csf1r的抗体
|
WO2011163424A2
(fr)
|
2010-06-22 |
2011-12-29 |
University Of Central Florida Research Foundation, Inc. |
Analogues d'acide 2-(9h-purin-9-yl)acétique substitués en tant qu'inhibiteurs de stat3
|
US9765019B2
(en)
|
2010-06-30 |
2017-09-19 |
Brandeis University |
Small-molecule-targeted protein degradation
|
KR20130121818A
(ko)
|
2010-08-02 |
2013-11-06 |
유니버시티 오브 센트럴 플로리다 리서치 파운데이션, 인코포레이티드 |
Stat 단백질의 저해제로서의 치환된 2-히드록시-4-(2-(페닐설폰아미도)아세트아미도)벤조산 유사체
|
CN105481983B
(zh)
|
2010-09-09 |
2021-09-03 |
辉瑞公司 |
4-1bb结合分子
|
CN103502275A
(zh)
|
2010-12-07 |
2014-01-08 |
耶鲁大学 |
融合蛋白的小分子疏水性标记和引起的其降解
|
WO2012078982A2
(fr)
|
2010-12-09 |
2012-06-14 |
The Ohio State University |
Xzh-5 inhibe la phosphorylation de stat3 constitutive et induite par l'interleukine 6 dans des cellules de carcinome hépatocellulaire humain
|
SG190997A1
(en)
|
2010-12-09 |
2013-07-31 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
WO2012097351A1
(fr)
|
2011-01-14 |
2012-07-19 |
The Ohio State University Research Foundation |
Matériels et procédés d'inhibition de cellules cancéreuses de myélome multiple
|
WO2012142615A2
(fr)
|
2011-04-14 |
2012-10-18 |
Board Of Regents, The University Of Texas System |
Auranofine et analogues d'auranofine utiles pour traiter une maladie proliférative et des troubles prolifératifs
|
NO2694640T3
(fr)
|
2011-04-15 |
2018-03-17 |
|
|
RS57324B1
(sr)
|
2011-04-20 |
2018-08-31 |
Medimmune Llc |
Antitela i drugi molekuli koji vezuju b7-h1 i pd-1
|
EA036814B9
(ru)
|
2011-11-28 |
2021-12-27 |
Мерк Патент Гмбх |
Антитело против pd-l1 (варианты), композиция, содержащая это антитело, и их применение
|
MX356337B
(es)
|
2011-12-15 |
2018-05-23 |
Hoffmann La Roche |
Anticuerpos contra csf-1r humano y sus usos.
|
EP3608317A1
(fr)
|
2012-01-12 |
2020-02-12 |
Yale University |
Composés et procédés pour la dégradation améliorée de protéines cibles et d'autres polypeptides par une e3 ubiquitine ligase
|
WO2013106646A2
(fr)
|
2012-01-12 |
2013-07-18 |
Yale University |
Composés et procédés pour l'inhibition de l'ubiquitine ligase vcb e3
|
KR20140127855A
(ko)
|
2012-02-06 |
2014-11-04 |
제넨테크, 인크. |
Csf1r 억제제를 사용하는 조성물 및 방법
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
EP3539984A1
(fr)
|
2012-05-11 |
2019-09-18 |
Five Prime Therapeutics, Inc. |
Procédés de traitement de maladies avec des anticorps qui se lient au récepteur 1 du facteur de stimulation de colonie (csf1r)
|
CN110003104A
(zh)
|
2012-05-25 |
2019-07-12 |
多伦多大学管理委员会 |
水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法
|
EP3406598B1
(fr)
|
2012-06-14 |
2020-01-29 |
Mayo Foundation for Medical Education and Research |
Dérivés de pyrazole en tant qu'inhibiteurs de stat3
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
KR102146848B1
(ko)
|
2012-08-09 |
2020-08-21 |
셀진 코포레이션 |
3-(4-((4-모르포리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온을 이용한 암의 치료방법
|
US9783513B2
(en)
|
2012-08-16 |
2017-10-10 |
Ohio State Innovation Foundation |
STAT3 inhibitors and their anticancer use
|
SG10201906328RA
(en)
|
2012-08-31 |
2019-08-27 |
Five Prime Therapeutics Inc |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
US9422331B2
(en)
|
2012-09-19 |
2016-08-23 |
Hoffmann-La Roche Inc. |
2-oxo-2,3,4,5-tetrahydro-1 H-benzo[B]diazepines and their use in the treatment of cancer
|
USRE48175E1
(en)
|
2012-10-19 |
2020-08-25 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
WO2014070859A1
(fr)
|
2012-10-30 |
2014-05-08 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Inhibiteurs de dimérisation de stat3
|
GB201311910D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel Compounds
|
US9777144B2
(en)
|
2013-03-15 |
2017-10-03 |
Zeon Corporation |
Aqueous dispersion of hollow polymer particles and method of production of same
|
US9802888B2
(en)
|
2013-03-22 |
2017-10-31 |
University Of Hawaii |
STAT3 inhibitors
|
EP2994143A4
(fr)
|
2013-05-08 |
2017-02-01 |
Board of Regents, The University of Texas System |
Inhibiteurs de stat6
|
WO2014205416A1
(fr)
|
2013-06-20 |
2014-12-24 |
University Of Hawaii |
Nouveaux inhibiteurs de stat3 sesquiterpénoïdes
|
WO2015071393A1
(fr)
|
2013-11-18 |
2015-05-21 |
F. Hoffmann-La Roche Ag |
Tétrahydro-benzodiazépinones
|
US20160058872A1
(en)
|
2014-04-14 |
2016-03-03 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
KR20240038809A
(ko)
|
2014-04-14 |
2024-03-25 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
|
EP3160486B1
(fr)
|
2014-06-27 |
2020-11-18 |
Celgene Corporation |
Compositions et procédés pour induire des modifications conformationnelles dans céréblon et d'autres ubiquitine ligases e3
|
US20160022642A1
(en)
|
2014-07-25 |
2016-01-28 |
Yale University |
Compounds Useful for Promoting Protein Degradation and Methods Using Same
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
KR101697062B1
(ko)
|
2014-08-26 |
2017-01-18 |
한국생명공학연구원 |
물에 대한 용해도가 개선된 신규 제라닐 프라보노이드 유도체, 이의 제조 방법 및 이를 유효성분으로 포함하는 암 예방 및 치료용 약학적 조성물
|
KR20160066490A
(ko)
|
2014-12-02 |
2016-06-10 |
주식회사 씨앤드씨신약연구소 |
헤테로사이클 유도체 및 그의 용도
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
CN107257800B
(zh)
|
2014-12-23 |
2020-06-30 |
达纳-法伯癌症研究所股份有限公司 |
通过双功能分子诱导靶蛋白降解的方法
|
WO2016115455A2
(fr)
|
2015-01-15 |
2016-07-21 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
3-(1h-pyrazol-5-yl)-7h-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines 6-aryl-7-substituées en tant qu'inhibiteurs de la voie stat3 ayant une activité anti-proliférative
|
US20170327469A1
(en)
|
2015-01-20 |
2017-11-16 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
EP3750530A1
(fr)
|
2015-02-05 |
2020-12-16 |
TyrNovo Ltd. |
Combinaisons de doubles modulateurs d'irs/stat3 et d'agents anticancéreux pour le traitement du cancer
|
CN108601764A
(zh)
|
2015-03-18 |
2018-09-28 |
阿尔维纳斯股份有限公司 |
用于靶蛋白的增强降解的化合物和方法
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
ES2862469T3
(es)
|
2015-06-04 |
2021-10-07 |
Arvinas Operations Inc |
Moduladores de proteólisis a base de imidas y métodos de uso asociados
|
EP3302482A4
(fr)
|
2015-06-05 |
2018-12-19 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs et procédés d'utilisation associés
|
SE539204C2
(en)
|
2015-06-05 |
2017-05-09 |
Glactone Pharma Dev Ab |
Ether analogues of galiellalactone
|
CN105085620B
(zh)
|
2015-06-25 |
2018-05-08 |
中山大学附属第一医院 |
一种靶向泛素化降解Smad3的化合物
|
WO2017007612A1
(fr)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Procédés pour induire la dégradation ciblée de protéines par des molécules bifonctionnelles
|
KR20180035828A
(ko)
|
2015-07-10 |
2018-04-06 |
아비나스 인코포레이티드 |
단백질 분해의 mdm2계 조절인자 및 관련된 이용 방법
|
WO2017011590A1
(fr)
|
2015-07-13 |
2017-01-19 |
Arvinas, Inc. |
Modulateurs de protéolyse à base d'alanine et procédés d'utilisation associés
|
JP6802251B2
(ja)
|
2015-07-14 |
2020-12-16 |
ミッション セラピューティクス リミティド |
癌の処置のためのdub阻害剤としてのシアノピロリジン
|
WO2017030814A1
(fr)
|
2015-08-19 |
2017-02-23 |
Arvinas, Inc. |
Composés et procédés pour la dégradation ciblée de protéines contenant un bromodomaine
|
AU2016323613B2
(en)
|
2015-09-18 |
2020-12-10 |
Merck Patent Gmbh |
Heteroaryl compounds as IRAK inhibitors and uses thereof
|
AU2016349781A1
(en)
|
2015-11-02 |
2018-05-10 |
Yale University |
Proteolysis targeting chimera compounds and methods of preparing and using same
|
US20200216454A1
(en)
|
2015-12-30 |
2020-07-09 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional molecules for her3 degradation and methods of use
|
WO2017117474A1
(fr)
|
2015-12-30 |
2017-07-06 |
Dana-Farber Cancer Institute, Inc. |
Composés bifonctionnels destinés à la dégradation d'her3 et procédés d'utilisation
|
MX2018011216A
(es)
|
2016-03-16 |
2019-08-29 |
H Lee Moffitt Cancer Ct & Res |
Moléculas pequeñas contra cereblon para mejorar la función efectora de los linfocitos t.
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
JP7001614B2
(ja)
|
2016-04-06 |
2022-02-03 |
ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン |
リガンド依存性の標的タンパク質分解のための単官能性中間体
|
UA123786C2
(uk)
|
2016-04-06 |
2021-06-02 |
Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган |
Деструктори білка mdm2
|
WO2017197056A1
(fr)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Dégronimères ciblant un bromodomaine pour la dégradation de protéines cibles
|
WO2017197036A1
(fr)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Dégronimères spirocycliques pour la dégradation de protéines cibles
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
CN109562107A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的杂环降解决定子体
|
WO2017201069A1
(fr)
|
2016-05-18 |
2017-11-23 |
Biotheryx, Inc. |
Dérivés d'oxoindoline utilisés comme modulateurs de la fonction protéique
|
CN109152843A
(zh)
|
2016-05-20 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
Protac抗体缀合物及其使用方法
|
GB201610147D0
(en)
|
2016-06-10 |
2016-07-27 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
CN110234646A
(zh)
|
2016-11-01 |
2019-09-13 |
阿尔维纳斯股份有限公司 |
靶向PROTAC的Tau蛋白及相关使用方法
|
AU2017363313B2
(en)
|
2016-11-22 |
2021-06-24 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
|
SE540295C2
(en)
|
2016-12-05 |
2018-05-29 |
Glactone Pharma Dev Ab |
Sulfonamide analogues of galiellalactone
|
WO2018136935A1
(fr)
|
2017-01-23 |
2018-07-26 |
University Of Hawaii |
Inhibiteurs de stat3 dérivés de 2-arylsulfonamido-n-arylacétamide
|
KR20190116315A
(ko)
|
2017-01-31 |
2019-10-14 |
아비나스 오퍼레이션스, 인코포레이티드 |
세레블론 리간드 및 이를 포함하는 이작용성 화합물
|
WO2018237026A1
(fr)
|
2017-06-20 |
2018-12-27 |
C4 Therapeutics, Inc. |
Dégrons et dégronimères à liaison n/o pour la dégradation de protéines
|
CN118108706A
(zh)
|
2017-09-04 |
2024-05-31 |
C4医药公司 |
戊二酰亚胺
|
IL295603B2
(en)
|
2017-09-22 |
2024-03-01 |
Kymera Therapeutics Inc |
Protein compounds and their uses
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
WO2019084030A1
(fr)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
Composés de (4-hydroxypyrrolidin-2-yl)-hydroxamate et leurs procédés d'utilisation
|
WO2019084026A1
(fr)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
Composés (4-hydroxypyrrolidin-2-yl)-hétérocycliques et leurs procédés d'utilisation
|
WO2019099868A2
(fr)
|
2017-11-16 |
2019-05-23 |
C4 Therapeutics, Inc. |
Agents de dégradation et dégrons pour dégradation protéique ciblée
|
EP3710443A1
(fr)
|
2017-11-17 |
2020-09-23 |
Arvinas Operations, Inc. |
Composés et procédés pour la dégradation ciblée de polypeptides de kinase 4 associés au récepteur de l'interleukine 1
|
AU2018396142A1
(en)
|
2017-12-26 |
2020-07-16 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
EP3737666A4
(fr)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Agents de dégradation de protéines et utilisations associées
|
EP3737675A4
(fr)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Ligands crbn et leurs utilisations
|
US11802132B2
(en)
|
2018-02-23 |
2023-10-31 |
Dana-Farber Cancer Institute, Inc. |
Small molecules for inducing selective protein degradation and uses thereof
|
EP3578561A1
(fr)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spirocomposés
|
WO2020010210A1
(fr)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Agents de dégradation de mertk et leurs utilisations
|
US20220348556A1
(en)
|
2018-07-06 |
2022-11-03 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
WO2020010177A1
(fr)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Ligands crbn tricycliques et leurs utilisations
|
CA3119773A1
(fr)
|
2018-11-30 |
2020-06-04 |
Kymera Therapeutics, Inc. |
Agents de degradation de kinases de type irak et leurs utilisations
|
CA3134822A1
(fr)
|
2019-03-26 |
2020-10-01 |
The Regents Of The Universtiy Of Michigan |
Agents de degradation, a petites molecules, de stat3
|
WO2020205467A1
(fr)
*
|
2019-03-29 |
2020-10-08 |
The Regents Of The University Of Michigan |
Agents de dégradation de protéines stat3
|
CA3135802A1
(fr)
|
2019-04-05 |
2020-10-08 |
Kymera Therapeutics, Inc. |
Agents de degradation de stat et leurs utilisations
|
WO2020264499A1
(fr)
|
2019-06-28 |
2020-12-30 |
Kymera Therapeutics, Inc. |
Agents de dégradation d'irak et leurs utilisations
|
WO2020264490A1
(fr)
|
2019-06-28 |
2020-12-30 |
Kymera Therapeutics, Inc. |
Agents de dégradation d'irak et leurs utilisations
|
US20220281831A1
(en)
|
2019-07-15 |
2022-09-08 |
Kymera Therapeutics, Inc. |
Fused-glutarimide crbn ligands and uses thereof
|
WO2021011634A1
(fr)
|
2019-07-15 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Agents de dégradation de protéines et leurs utilisations
|
WO2021011871A1
(fr)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Agents de dégradation de mertk et leurs utilisations
|
US20230132715A1
(en)
|
2019-07-17 |
2023-05-04 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
EP4072591A4
(fr)
|
2019-12-10 |
2024-06-05 |
Kymera Therapeutics, Inc. |
Agents de dégradation d'irak et leurs utilisations
|
EP4076536A4
(fr)
|
2019-12-17 |
2024-05-01 |
Kymera Therapeutics, Inc. |
Agents de dégradation d'irak et leurs utilisations
|
JP2023509366A
(ja)
|
2019-12-17 |
2023-03-08 |
カイメラ セラピューティクス, インコーポレイテッド |
Irak分解剤およびそれらの使用
|
WO2021127283A2
(fr)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Agents de dégradation d'irak et leurs utilisations
|
WO2021158634A1
(fr)
|
2020-02-03 |
2021-08-12 |
Kymera Therapeutics, Inc. |
Agents de dégradation de kinases irak et leurs utilisations
|
EP4121055A4
(fr)
|
2020-03-17 |
2024-04-24 |
Kymera Therapeutics, Inc. |
Agents de dégradation de stat et leurs utilisations
|
WO2021195481A1
(fr)
|
2020-03-26 |
2021-09-30 |
The Regents Of The University Of Michigan |
Agents de dégradation de protéine stat à petites molécules
|
US20240293423A1
(en)
|
2020-10-07 |
2024-09-05 |
Kymera Therapeutics, Inc. |
Stat degraders and uses thereof
|
IL313123A
(en)
|
2021-12-11 |
2024-07-01 |
Kymera Therapeutics Inc |
STAT3 compounds and their uses
|